hotspot -WSS

hotspot

author：comprehensive 2025-09-02 11:39:03 - browse：4967

Adobe

The medical device industry is split on whether a proposed new Medicare reimbursement pathway will do anything to soothe their insurance coverage woes.

Device makers have long complained that the unclear, rocky road to payment kills innovative companies. So they were thrilled when the Trump administration proposed a rule that would have guaranteed four years of Medicare coverage of approved devices deemed “breakthroughs” by the Food and Drug Administration. They hoped private payers would follow suit. But in 2021, under a new administration and a push for more device scrutiny, the Centers for Medicare and Medicaid pulled back on the idea, promising a replacement that would streamline coverage for innovative devices while ensuring safe, high-quality care.

The pathway put forth last week, called Transitional Coverage for Emerging Technologies (TCET), is only a notice, not yet a rule that would grant CMS new powers. The program applies solely to devices that have earned a place in the FDA’s breakthrough device program, which was established to identify devices that the agency believed could provide “more effective” treatment or diagnosis of serious conditions than the current standard of care. But because those devices can be brought to market with less certainty in their benefits and risks than other products, experts said, the idea of automatic reimbursement was dicey.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Stroke deaths set to near 10 million globally by 2050

WSS

Bill would stop addiction treatment from triggering child abuse inquiry

When women are denied an abortion, their children fare worse than peers

Stroke deaths set to near 10 million globally by 2050

What to expect at HLTH 2023, the health care industry conference

Covid isolation guidance eased by the CDC

RSV vaccines may be linked to small increased risk of developing GBS

knowledge

hotspot

hotspot

What does generative AI mean for health care? We asked experts

Bristol 'take

Virginia high school admissions case could be legal follow

An inside look at PIPEs, biotech's buzzy new financing tool

The high cost of giving birth even with insurance

Histogen: Failed biotech offers rare public look inside

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

Bright Health sells Medicare Advantage business to Molina

Chemotherapy drug shortage eases slightly but still widespread

knowledge

What to expect at HLTH 2023, the health care industry conference

VC firm General Catalyst wants to buy a health system

Flu vaccine offering decent levels of protection this winter, new data show

In search for therapies for solid tumors, companies turn to claudin

Covid isolation guidance eased by the CDC

Bristol 'take

entertainment

Wikipedia

focus

focus